Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 28,087 | 32,501 | 15,717 | 7,973 | 86,581 |
| Cost of Goods | 6,154 | 8,191 | 4,984 | 1,094 | 865 |
| Gross Profit | 21,933 | 24,310 | 10,733 | 6,879 | 85,716 |
| Operating Expenses | 63,552 | 77,693 | 59,331 | 44,150 | 39,384 |
| Operating Income | -41,465 | -53,192 | -47,614 | -37,177 | 47,197 |
| Other Income | 61 | 2,041 | 2,731 | 3,237 | 3,025 |
| Pre-tax Income | -41,404 | -51,151 | -44,883 | -33,940 | 50,222 |
| Net Income Continuous | -41,324 | -51,151 | -44,883 | -33,940 | 49,934 |
| Net Income | $-41,324 | $-51,151 | $-44,883 | $-33,940 | $49,934 |
| EPS Basic Total Ops | -0.41 | -0.52 | -0.46 | -0.35 | 0.52 |
| EPS Basic Continuous Ops | -0.42 | -0.52 | -0.46 | -0.35 | 0.52 |
| EPS Diluted Total Ops | -0.41 | -0.52 | -0.46 | -0.35 | 0.52 |
| EPS Diluted Continuous Ops | -0.42 | -0.52 | -0.46 | -0.35 | 0.51 |
| EPS Diluted Before Non-Recurring Items | -0.42 | -0.52 | -0.46 | -0.35 | 0.52 |
| EBITDA(a) | $-42,051 | $-53,893 | $-48,802 | $-38,858 | $45,682 |